| __timestamp | Geron Corporation | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 8901000 | 21226345 |
| Thursday, January 1, 2015 | 9574000 | 139626 |
| Friday, January 1, 2016 | 14695000 | 93831530 |
| Sunday, January 1, 2017 | 8437000 | 79419009 |
| Monday, January 1, 2018 | 12723000 | 368673 |
| Tuesday, January 1, 2019 | 51272000 | 477121 |
| Wednesday, January 1, 2020 | 50052000 | 1895029 |
| Friday, January 1, 2021 | 783000 | 8034589 |
| Saturday, January 1, 2022 | 868000 | 20443000 |
| Sunday, January 1, 2023 | 123740000 | 33745000 |
Unlocking the unknown
In the competitive world of biotechnology, cost efficiency is paramount. This analysis compares the cost of revenue efficiency between Intra-Cellular Therapies, Inc. and Geron Corporation from 2014 to 2023. Over this period, Intra-Cellular Therapies demonstrated a significant fluctuation in cost efficiency, peaking in 2016 with a cost of revenue nearly 400% higher than its 2015 figure. Meanwhile, Geron Corporation maintained a more stable trajectory, with a notable spike in 2023, where its cost of revenue surged by over 1400% compared to 2022. This data highlights the dynamic nature of financial management in biotech firms, where strategic investments and operational costs can vary dramatically year over year. Understanding these trends is crucial for investors and stakeholders aiming to navigate the volatile biotech landscape.
Cost Insights: Breaking Down Novo Nordisk A/S and Geron Corporation's Expenses
Cost of Revenue: Key Insights for AbbVie Inc. and Geron Corporation
Analyzing Cost of Revenue: Novartis AG and Geron Corporation
Cost of Revenue Comparison: Sanofi vs Intra-Cellular Therapies, Inc.
Cost Insights: Breaking Down Vertex Pharmaceuticals Incorporated and Geron Corporation's Expenses
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs Geron Corporation
Comparing Cost of Revenue Efficiency: Viatris Inc. vs Geron Corporation
Intra-Cellular Therapies, Inc. vs Sarepta Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Intra-Cellular Therapies, Inc. vs HUTCHMED (China) Limited
Agios Pharmaceuticals, Inc. vs Geron Corporation: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Geron Corporation vs Iovance Biotherapeutics, Inc.
Analyzing Cost of Revenue: Geron Corporation and Wave Life Sciences Ltd.